In vivo recruitment of hematopoietic cells using stromal cell-derived factor 1 alpha-loaded heparinized three-dimensional collagen scaffolds. by Bladergroen, B.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/80271
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
In Vivo Recruitment of Hematopoietic Cells Using
Stromal Cell–Derived Factor 1 Alpha–Loaded Heparinized
Three-Dimensional Collagen Scaffolds
Bellinda A. Bladergroen, Ph.D.,1 Bas Siebum, Ph.D.,2 Kim G.C. Siebers-Vermeulen, B.Sc.,1
Toin H. Van Kuppevelt, Ph.D.,3 Andre´ A. Poot, Ph.D.,2 Jan Feijen, Ph.D.,2
Carl G. Figdor, Ph.D.,1 and Ruurd Torensma, Ph.D.1
Implantable three-dimensional (3D) constructs to engineer tissue have great therapeutic potential in regenerative
medicine and immunotherapy. However, autonomous recruitment of cells into the engineered scaffold in vivo is
hampered by lack of attracting scaffolds. As a first step to engineering immune tissue, 3D collagen scaffolds were
investigated for their ability to enhance in vivo recruitment and growth of various hematopoietic cells. Scaffolds
containing immobilized heparin to trap the stem cell chemo-attractant stromal cell–derived factor 1 alpha (SDF1a)
were implanted subcutaneously into C57Bl6 mice, and influx of cells was monitored using immunohistochem-
istry. Five weeks post-implantation, heparinized scaffolds were always populated by cells, but incorporating
SDF1a considerably stimulated recruitment of cells. SDF1a could not exert this effect when the formation of a
SDF1a gradient was abrogated. Scaffolds were mainly populated by CD11bþ and CD11cþ myeloid cells and
fibroblasts. One week after implantation, scaffolds harbored only low numbers of cells. Apparently, not all
CXCR4-expressing cells, like large numbers of granulocytes, migrate into the scaffold, but retransplantation of a 1-
week-old scaffold from a CD45.2þ into a CD45.1þmouse yielded a scaffold harboringmainly CD45.2þ cells after 5
weeks. These data confirm that only a few progenitor cells are recruited early after implantation. These cells then
proliferate and differentiate along different lineages and determine the outcome after 5 weeks.
Introduction
Tissue engineering using implantable three-dimensional(3D) constructs with autologous cells emerges as a prom-
ising approach of cellular therapy for several diseases.1–3
Mesenchymal and hematopoietic stem cells (HSCs) have
great therapeutic potential in regenerative medicine, trans-
plantation, and immunotherapy. Mechanisms exploited by
nature’s tissue engineering are the guidelines for artificial
scaffolds used for in vivo tissue engineering.4 The HSC is the
best-characterized adult stem cell, and recent advances in
purification techniques have improved the purity with which
HSCs can be isolated from mouse and human bone mar-
row,5–7 but despite progress in purification technology and
the characteristic ability of stem cells to self-renew, huge
expansion of HSCs in vitro has been unsuccessful. Moreover,
ex vivo processing of cells is time- and cost-consuming.
Limited expansion of undifferentiated adult stem cells has
been a major obstacle for clinical applications of these cells.
In vivo, maintenance of HSCs and regulation of their pro-
liferation and differentiation depends on their residence
in special micro-environments, called stem cell niches.8–10
Therefore, an alternative for in vitro expansion and processing
might be in vivo recruitment to and growth of HSCs in a sup-
portive scaffold with a micro-environment resembling the
stem cell niche. Such a scaffold should allow local concen-
tration, expansion, and manipulation in directing stem cell
differentiation toward the cell types required therapeutically.
In bone marrow, stem cell niches comprise hematopoietic
and stromal cells that create a complex but unique network
of growth factors, chemokines, extracellular matrix, and ad-
hesion molecules.8,9,11 During homeostasis, HSCs are not
confined to bone marrow niches; a small number of HSCs are
released into the circulation, and circulating HSCs return to
the bone marrow niche again. Furthermore, in response to
signals from the periphery after injury, HSCs can move out
of and into the bone marrow. Transplanted HSCs rapidly
migrate to the bone marrow of the recipient.8,12
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The factor that plays a key role in the regulation of HSC
homing and mobilization is the chemokine CXCL12, also
known as stromal cell–derived factor 1 (SDF1) (reviewed in 8
and12). In bone marrow, osteoblasts, vascular endothelial
cells, and fibroblasts produce SDF1. It functions as a chemo-
attractant by forming a gradient between bone marrow and
blood.13–15 It has been shown that purified HSCs migrate
specifically toward SDF1 and not toward other chemokines.16
SDF1 exerts its effects by binding to the receptor CXCR4,
which HSCs and hematopoietic progenitor cells (HPCs) ex-
press.17,18 Although HSCs appeared to respond specifically
to SDF1, SDF1 probably does not specifically control the traf-
ficking of HSCs, because other cells express CXCR4 as well.
For example, monocytes19 and bone marrow stromal stem
cells20 also express CXCR4. Furthermore, the interaction be-
tween SDF1 and CXCR4 is essential for early B-cell devel-
opment and the homing of end-stage B cells to the bone
marrow.9,21
In bone marrow, glycosaminoglycans (GAGs) can bound
and present SDF1.14,22 Binding and tethering soluble factors
such as growth factors and chemokines is one mechanism by
which GAGs contribute to the formation of stem cell niches
and regulate hematopoietic processes. Heparan sulfate, but
also chondroitin sulfate and dermatan sulfate, which are
present on the cell surface of bone marrow endothelial cells,
guide migration of HPCs by binding and presenting SDF1.
Moreover, in vitro studies suggest that endothelial heparan
sulfate proteoglycans also control homing of HOCs by acting
as direct adhesive ligands.23
As a first step in engineering immune tissue, 3D collagen
scaffolds were used to recruit and support growth of hema-
topoietic cells in C57Bl6 mice. To improve the attracting and
growth-supporting capacities of the scaffold, the effects of
SDF! Slpha (SDF1a) and heparin on the population of the
scaffolds by hematopoietic cells were investigated.
Materials and Methods
Mice
The animal experiments committee of the Radboud Uni-
versity Nijmegen Medical Centre (RUNMC) approved all an-
imal experiments. C57Bl6 (N) mice were bred at the Central
Animal Laboratory of the RUNMC. Adult C57Bl6.SJL-
CD45.2 mice were purchased from Charles River Labora-
tories (L’Arbresle, France) and C57Bl6.SJL-CD45.1 mice were
kindly provided by dr. R. van der Voort (Central Hematol-
ogy Laboratory, RUNMC) but originated from Jackson La-
boratory (Bar Harbor, ME) (stock no. 002014). CD45.1 and
CD45.2 mice differ only slightly in their CD45 membrane
molecule. CD45 is a marker molecule for leukocytes. Neither
strain rejects cells from the other. Monoclonal antibodies to
both CD45 variants are available, allowing the identification
of the origin of the cells in the scaffold. All mice were housed
in the specific pathogen–free unit of the Central Animal
Laboratory at RUNMC.
Materials
Insoluble type I collagen from bovine Achilles tendon
and heparin from porcine intestinalmucosa (molecular weight
(MW) 6,000–30,000, activity *200 IU=mg) were purchased
from Sigma (St. Louis, MO). N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (EDC), N-hydroxy-
succinimide (NHS), and 2,4,6-trinitrobenzenesulfonic acid
were obtained from Fluka (Buchs, Switzerland). Recombinant
human SDF1awas from R&D Systems (Minneapolis, MN).
Biotinylated monoclonal antibodies (mAbs) anti-CD11b
mAb M1=70 (subtype rat immunoglobulin G2b (rIgG2b));
anti-CD45.1 mAb A20 (mouse IgG2a kappa (mIgG2a,k)); and
anti-CD45.2 mAb 104, purified anti-CD16=CD32 mAb 2.4G2,
purified rat IgG2a,k and IgG2b,k; and purified hamster
IgG,k (haIgG,k) were purchased from BD Pharmingen (San
Diego, CA). Biotinylated mAbs anti-CD11c mAb N418 (Ar-
menian hamster IgG), anti-CD45R=B220 mAb RA3-6B2
(rIgG2a), anti-CD3 mAb 145-2C11 (haIgG), and anti-CD48
mAb HM48-1 (Armenian haIgG) were obtained from e-
Bioscience (San Diego, CA), and biotinylated anti-CD41 mAb
MW Reg30 (rIgG1) was from Serotec (Oxford, United
Kingdom). Supernatant containing antibody ERTR7 (rIgG2a)
was a kind gift from dr. R. Mebius (Department of Molecular
Cell Biology and Immunology, Vrije Universiteit Medical
Center, Amsterdam, the Netherlands), and anti-CD150 mAb
26D12 (rIgG1) was kindly provided by dr. R. de Waal Mal-
efijt (DNAX, Palo Alto, CA). Anti-CD31 mAb MEC7.46
(rIgG2a) was from Hycult (Uden, the Netherlands), and
biotinylated goat-anti-rat IgG was from Molecular Probes
(Eugene, OR). Streptavidin-biotin-horseradish peroxidase
complex (ABCPO), streptavidin-biotin-alkaline phosphatase
complex (ABCAP), and levamisole were from Vector La-
boratories, Inc. (Burlingame, CA). FastRed TR and naphthol
AS-TR phosphate were obtained from Sigma, and optimal
cutting temperature embedding matrix (Tissuetek) was from
Cell Path (Newtown, Wales, United Kingdom).
Preparation of collagen scaffolds
Collagen suspensions were prepared by swelling 2%
(w=v) insoluble type I collagen in 0.5M acetic acid at 48C
overnight. After dilution to 1% (w=v) collagen by addition of
crushed ice, the suspension was dispersed for 4min in a
Philips Blender and subsequently homogenized at 48C for
30min using an Ultra-Turrax T25 (IKA Labortechnik, Stau-
fen, Germany). The resulting slurry was filtrated through a
20-denier nylon stocking (with an average pore size of 30mm)
and a 25-mm Cellector screen filter (Bellco, Feltham, United
Kingdom) mounted in a disc filter holder. Entrapped air
bubbles were removed by degassing at 0.1mbar. The sus-
pension was frozen overnight at 258C in polystyrene trays
and lyophilized.
Dried collagen matrices were chemically cross-linked
with EDCandNHS.24Dried scaffoldswere incubated in 0.05M
2-(N-morpholino)ethanesulfonic acid buffer pH 5.5 for 30min
at room temperature. Subsequently, scaffolds were cross-
linked using gentle shaking for 2 h in a 2-(N-morpholi-
no)ethanesulfonic acid buffer containing 55.8mM of EDC and
22.6mM of NHS. The reaction was stopped by washing in
0.1M sodium phosphate for 2 h, followed by rinsing three
times for 30min with demineralized water.
Immobilization of heparin
Heparin was attached to EDC=NHS cross-linked collagen
scaffolds for 2 h as described.24 Control scaffolds were sub-
jected to the same procedure except for the addition of
heparin. The heparin content of cross-linked scaffolds was
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determined using a colorimetric assay based on the binding
of toluidine blue.25
Characterization of scaffolds
After fixation with 2% glutaraldehyde (v=v) and 50% (v=v)
osmium oxide the 3D structure of heparinized and non-
heparinized scaffolds was evaluated using scanning electron
microscopy.26 The residual number of free primary amine
groups of cross-linked and un-cross-linked collagen matrices
was measured spectrophotometrically after reaction with
trinitrobenzenesulfonic acid.27 The shrinkage temperature (Ts)
was determined using differential scanning calorimetry.28
Determination of SDF1a binding and release
Recombinant human SDF1a was labeled with 125Iodine
(125I) using Iodobeads as described previously (Pierce,
Bioscience Etten-Leur, The Netherlands).29 Collagen scaf-
folds (4mg dry weight) with and without immobilized
heparin were incubated overnight at 378 C in a solution of
penicillin (200U=mL) and streptomycin (200mg=mL). After
being rinsed three times with phosphate buffered saline
(PBS), the scaffolds were incubated overnight at room tem-
perature in 1mL of a solution of PBS with 2.22 mg=mL of
125I-labelled SDF1a. Subsequently, scaffolds were rinsed
three times with PBS, and radioactivity was measured using
a Compugamma 1282 g-counter (LKB, Stockholm, Sweden).
To determine the release of SDF1a, scaffolds that had been
pre-absorbed with 125I-labelled SDF1a were incubated at
378C in 5mL of human plasma supplemented with 0.02%
sodium azide. The medium was refreshed twice a week, and
radioactivity in the medium was measured each time. After 2
weeks, the remaining radioactivity in the scaffolds was
measured as well.
Implantation of collagen scaffolds into C57Bl6 mice
Six-mm-diamter punches of heparinized and non-
heparinized collagen scaffolds were sterilized by immersion
in 70% ethanol for at least 6 h. After being washed 10 times
with sterile PBS, scaffolds were incubated in a solution of
PBS containing 0.1% (w=v) bovine serum albumin (BSA)
with or without 2mg=mL of recombinant human SDF1a for
18 to 42 h at room temperature. In case scaffolds were sub-
jected to a SDF1a-washout, an 18-h incubation with SDF1a in
PBS=0.1% BSA was followed by an incubation for another
24 h at room temperature in PBS. All collagen punches were
quickly rinsed three times in PBS and immediately used for
implantation into C57Bl6(N) mice.
Six-mm punches were implanted subcutaneously via an
incision in the back after the mice were anesthetized with
isoflurane inhalation. Each mouse usually received two
punches of the same type of scaffold. At 1 or 5 weeks post-
implantation, scaffold punches were collected, immediately
embedded in Tissuetek, and frozen in liquid nitrogen. Sam-
ples were stored at 808C until further analysis.
To examine the recruitment of HPCs toward collagen
scaffolds, a transplantation experiment with C57Bl6.SJL mice
expressing different natural variants of CD45 was performed
as follows. Eight-mm punches of heparinized collagen scaf-
folds incubated with or without 2mg=mL of recombinant
human SDF 1a (rhSDF1a) in PBS=0.1% BSA were quickly
rinsed with PBS and immediately implanted subcutaneously
(one punch per mouse) into CD45.2þ C57Bl6.SJL mice as
described above. At 1 week post-implantation, punches were
collected and transplanted subcutaneously into C57Bl6.SJL
mice expressing CD45.1 (one punch per mouse). After an-
other 4 weeks in the CD45.1þ mice, scaffold punches were
collected and processed as described above.
Immunohistochemistry
Sections (5 mm thick) from frozen scaffolds were mounted
on poly-L-lysine–coated slides and dried. Cell density and
distribution were assessed on hematoxylin and eosin–stained
sections. To identify specific cell populations, immunohisto-
chemistry was performed with a panel of appropriate anti-
bodies against various cell markers. A summary of the
staining protocols is given in Table 1.
Sections were fixed with 4% paraformaldehyde for 30min
or in acetone for 5min. Endogenous peroxidase activity was
Table 1. Overview of the Staining Procedures for Various Cell Markers on Frozen Sections
of Three-Dimensional Collagen Scaffolds
Staining
Step
CD11b
Myeloid cells
CD11c
Dendritic cells
CD3
T-cells
B220
B-cells
ERTR7
Fibroblasts
CD31
Endothelial cells
CD45.1
Leucocytes
CD45.2
Leucocytes
Fixation PFA PFA acetone PFA acetone acetone acetone acetone
Peroxidase block þ þ þ þ    
Pre-incubation PBS=BSA PBS=BSA PBS=BSA PBS=BSA NGS NGS  
Primary Ab rIgG2b haIgG haIgG rIgG2a ERTR7 aCD31 CD16=CD32 CD16=CD32
Clone      MEC7.46 2.4G2 2.4G2
Concentration 5 mg=mL 5mg=mL 5 mg=mL 5 mg=mL 1:5 10mg=mL 5mg=mL 5 mg=mL
Secondary Ab aCD11bbio aCD11cbio aCD3bio aB220bio GaRbio GaRbio aCD45.1bio aCD45.2bio
Clone M1=70 N418 145-2C11 RA3-6B2   A20 104
Concentration 5mg=mLa 5mg=mL 20mg=mLa 5 mg=mLa 10mg=mLa 10mg=mLa 20 mg=mL 20mg=mL
Detection ABCPO ABCPO ABC PO ABCPO ABCAP ABCAP ABCAP ABCAP
Visualization DAB DAB DAB DAB FR FR FR FR
Ab, antibody; ABC, avidin-biotin complex; AP, alkaline phosphatase; bio, biotinylated; BSA, bovine serum albumin; DAB,
diaminobenzidine; FR, FastRed; NGS, normal goat serum; PFA, paraformaldehyde.
aAb diluted in buffer containing 2% normal mouse serum.
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blocked using incubation for 10min with 0.3% (v=v) hydro-
gen peroxide (H2O2) in PBS. Aspecific staining was blocked
using incubation for 10min with PBS=1% BSA or 20% (v=v)
normal goat serum. To identify marker proteins, sections
were sequentially incubated with the primary and secondary
antibodies at a final concentration as denoted in Table 1.
Incubation with each antibody was for 1 h at room temper-
ature. The secondary antibody was biotinylated and diluted
in PBS=1% BSA or PBS with 2% (v=v) normal mouse serum.
Biotinylated secondary antibodies were detected using
ABCPO or ABCAP. Bound antibodies were visualized using
incubation with diaminobenzidine=H2O2 or FastRed. Slides
were counterstained with hematoxylin and mounted. Ne-
gative control slides were stained with IgG of the appropri-
ate subclass.
CD150þCD41–CD48– hematopoietic stem cells were iden-
tified using triple staining as follows. After fixation with 4%
paraformaldehyde for 30min at room temperature, sections
were preincubated for 30min with 20% (v=v) normal donkey
serum diluted in confocal laser scanning microscopy (CLSM)
buffer (3% (w=v) BSA and 10mM of glycine in PBS). Sub-
sequently, sections were stained with anti-CD150 mAb
26D12 at 28 mg=mL for 1 h at room temperature. CD150 was
detected using incubation with APC-conjugated donkey-
anti-rat, IgG diluted 1:200 in CLSM. After blocking with 10%
(v=v) normal rat serum in CLSM, sections were then stained
for 1 h with biotinylated anti-CD41 mAb MW-Reg30 (diluted
1:100) and CD48 mAb HM48-1 (20 mg=mL) in CLSM with
10% (v=v) normal rat serum. Biotinylated antibodies were
visualized using incubation with Texas Red conjugated
streptavidin, and sections were mounted. Fluorescence was
analyzed using a Biorad confocal laser scanning microscope
(Biorad, Hercules, CA).
Results
Cross-linking of heparin to collagen scaffolds improves
their binding capacity for SDF1a
Three-dimensional collagen scaffolds consisted of a porous
structure with an average pore size of 130 mm, as evaluated
from scanning electron micrographs (Fig. 1A). Cross-linking
with EDC and NHS resulted in a decrease of free primary
amino groups from 27 to 16 per 1000 amino acid residues.
The shrinkage temperature increased from 598C for un-
cross-linked collagen to 718C for the cross-linked scaffolds.
Thirty-four 34 3mg heparin per mg of collagen was at-
tached to the scaffold, as measured according to the toluidine
blue assay. Toluidine blue staining also showed that heparin
had penetrated and had been attached to the collagen strains
throughout the scaffold, including the central part (data not
shown).
Upon overnight incubation in a solution with soluble
SDF1a, non-heparinized scaffolds bound approximately
50 ng of SDF1a per mg of cross-linked collagen. Cross-
linking heparin to collagen improved binding of SDF1a to
collagen scaffolds. Not only was the amount of SDF1a bound
to heparinized collagen higher (60 ng SDF1a per mg of hep-
arinized collagen), but the subsequent release from these
scaffolds was also slower (Fig. 1B). Washout experiments
showed that, from heparinized and non-heparinized collagen
scaffolds, more than 50% of initially bound SDF1a was re-
leased within 24 h after placing the scaffold in plasma
(Fig. 1). After 24 h, the percentage of initially bound che-
mokine still present on cross-linked scaffolds without and
with heparin was 35 7% and 49 3% (n¼ 3), respectively.
The first phase of rapid release was followed by a second
phase in which the rate of release gradually declined. After 2
weeks, 40% of initially bound SDF1a remained present in
heparinized collagen scaffolds. In non-heparinized scaffolds,
this was only 20%. In the following in vivo experiments,
heparinized collagen scaffolds were used, unless stated
otherwise.
SDF1a stimulates recruitment of cells
toward 3D heparin collagen scaffolds
After subcutaneous implantation, scaffolds always be-
came populated by cells. One week after implantation, cells
lying along the collagen fibers could be detected, although
cell numbers were low (Fig. 2A). They were not distributed
homogeneously throughout the scaffold, but most cells were
present in a few spots at the periphery or in an area just
around the scaffold. Five weeks after implantation, far more
cells had populated the scaffold. By that time, not only had
cell numbers increased, but their distribution had also
FIG. 1. (A) Scanning
electron micrograph of the
collagen scaffold. (B)
Heparinized (&) and
non-heparinized (~) cross-
linked three-dimensional
collagen scaffolds,
containing 125I-labelled
SDF1a, were incubated in
human plasma. The release
of radio labeled stromal
cell–derived factor 1 alpha
(SDF1a) into plasma was
measured over time, as described in Materials and Methods. The cumulative release of SDF1a is shown as a percentage
of the amount of radioactivity initially bound to the scaffold. Values are the means standard deviations (n¼ 3).
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changed (Fig. 2C). Now they were present almost through-
out the scaffold, including the central part.
To achieve better recruitment of cells toward the scaffolds,
the scaffolds were pre-incubated with SDF1a just before
implantation. Binding of SDF1a to a scaffold resulted in a
dramatic increase in the number of cells present 5 weeks after
implantation (Fig. 2D). Whereas in the absence of SDF1a,
space between collagen fibers was rather empty, even 5weeks
after implantation, scaffolds with bound SDF1a showed
pores that were completely filled with cells and newly
laid down extracellular matrixSDF1a could also exert its ef-
fects on cell recruitment when it was loosely absorbed by
collagen, although the effect was somewhat less than in the
presence of heparin. As can be seen in Figure 3, with or
without heparin, scaffolds containing SDF1a showed mark-
edly more cells recruited than scaffolds without SDF1a.
Heparin itself had hardly any effect on the number of cells
recruited to the scaffold. (Compare the scaffolds in Fig. 3D
and 3E with those in 3A and 3B.)
SDF1a could not exert its effect on cell recruitment any
more when its ability to form a gradient was abrogated. If
scaffolds containing SDF1a were incubated in PBS, at least
50% of SDF1a was released within 24 h from scaffolds with
and without heparin (Fig. 1). If scaffolds subjected to such a
24-h SDF1a-washout were then implanted in vivo, the level of
cell recruitment was as low as toward scaffolds that had not
been incubated with SDF1a at all (Fig. 3).
Hematopoietic and stromal cell types populated
SDF1a–treated heparinized collagen scaffolds
Five weeks after implantation, several cell types populated
SDF1a-soaked heparin collagen scaffolds (Fig. 4). Most he-
matopoietic cells were of the myeloid lineage, including
CD11bþ and CD11cþ cells (Fig. 4A, B). CD11cþ and CD11bþ
cells were scattered throughout the scaffold and were present
as single cells lying along the collagen fibers or in small cell
clusters. CD150þCD41–CD48– HSCs could be detected in the
scaffolds, although in low numbers (Fig. 4C). Moreover,
hardly any CD45R=B220þ B-cells or CD3þ T-cells were found.
In addition to hematopoietic cells, stromal cells had been
recruited to the scaffold. Expression of the fibroblast marker
ERTR7 was observed mainly at the periphery of the scaffold
(results not shown). Cells staining positive for CD31 indi-
cated formation of small vessels (Fig. 4D). No staining was
observed with isotype control mAbs (results not shown).
Hematopoietic cells present after 5 weeks
are mainly derived from cells recruited
early after implantation
Although at least a few CD150þCD41–CD48– HSCs were
found in some heparin collagen scaffolds 5 weeks after im-
plantation, no such HSCs could be detected after 1 week.
This probably reflects low numbers of these circulating
HSCs. To examine the recruitment of stem or progenitor cells
into these scaffolds, heparin collagen scaffolds were im-
planted into C57Bl6 mice expressing different natural vari-
ants of CD45. One week after implantation of scaffolds into
CD45.2-expressing mice, most of the recruited CD45.2þ cells
resided at the periphery of the scaffolds (Fig. 5A). When such
a scaffold was transplanted from a CD45.2- to a CD45.1-
expressing mouse, it contained considerably higher numbers
of CD45.2-positive cells after 4 weeks that were distributed
throughout the entire scaffold (Fig. 5C). Because these cells
could only have been derived from the CD45.2-expressing
FIG. 2. Pre-incubation of
three-dimensional heparin–
collagen scaffolds with
stromal cell–derived factor 1
alpha (SDF1a) markedly
enhances their population by
cells upon implantation.
Hematoxylin and eosin stain-
ing of sections of heparin–
collagen scaffolds incubated
without (A, C) and with (B, D)
SDF1a before implantation.
Scaffolds were collected 1
week (A, B) or 5 weeks (C, D)
post-implantation. Original
magnification:100. Experi-
ment was performed twice in
duplicate.
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mouse, this indicates that CD45.2þ stem or progenitor cells
were already present at the time of retransplantation. Dur-
ing the 4 weeks that the scaffolds resided in the CD45.1-
expressing mice, some CD45.1þ cells were recruited (Fig.
5D), but their numbers were low, and they stayed mainly at
the periphery of the scaffolds.
Discussion
The present data demonstrate a novel approach to at-
tracting circulating cells into a scaffold. This is a first step to
engineer tissue without seeding cells in the scaffold before
implantation. To promote cell attraction, we loaded the
scaffolds with SDF, a chemokine involved in homing of cir-
culating hematopoietic cells to the bone marrow. To create a
gradient of SDF, scaffolds were loaded with the chemokine.
Release kinetics indicated that the scaffold contained loosely
absorbed SDF1a that was released during the first 24 h and
SDF1a that was firmly bound by heparin in vitro. SDF1a is
released from heparinized 3D collagen scaffolds in two
phases, with a rapid release of 50% of initially present SDF1a
in the first 24 h followed by a much slower release of an
additional 10% in the weeks thereafter (Fig. 1B). Assuming a
similar release pattern in vivo, a gradient of SDF is present
during the first 24 h after implantation.
Binding of SDF1a to heparinized scaffolds was better than
binding to bare collagen scaffolds. Heparin itself had hardly
any effect on the number of cells recruited to collagen scaf-
folds. This is in contrast to what was expected, because hep-
arin and heparan sulfate proteoglycans (HSPGs) have been
reported to contribute significantly to formation of niches and
play a dominant role in the regulation of hematopoiesis,30
although in the latter situation, HSPGs carry trapped growth
factors. It has been hypothesized that HSPGs contribute to
homing of HPCs to bone marrow,14 are adhesive ligands for
adhesion molecules such as integrin CD11b=CD18,31 and
bind many chemokines and growth factors.22,32
The putative gradient of SDF1a formed during the first
phase of release appeared to be essential for cell recruitment
(Fig. 2), because abrogation of gradient formation by SDF1a
washout resulted in markedly fewer cells present in scaffolds
at 5 weeks after implantation (Fig. 3C, F). It has been re-
ported that SDF1a can mediate migration of T-cells without
the formation of a gradient when endothelial cells present
FIG. 3. The ability of stromal
cell–derived factor 1 alpha
(SDF1a) to form a gradient is
essential to stimulate cell re-
cruitment. Hematoxylin and
eosin staining of sections of
non-heparinized (A–C) and
heparinized (D–F) collagen
scaffolds incubated without
(A, D) or with (B, E) SDF1a or
subjected to a SDF1a washout
(C, F) before implantation. All
scaffolds were collected
5 weeks after implantation.
Original magnification:200.
Experiment was performed
twice in duplicate.
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it.33 However, in our scaffolds, hardly any T-cells were
found, although CD31þ endothelial cells were present.
SDF1a that remains bound to the scaffold is supposed to
retain cells in the scaffold, analogous to the involvement
of SDF1 in retention of hematopoietic cells within bone
marrow.34,35
HPCs are attracted within 1 week, and 5 weeks after im-
plantation, several cell types, such as CD11bþ and CD11cþ
myeloid cells and ERTR7þ fibroblasts, populate scaffolds.
Although heparin is needed to better bind SDF1a to collagen,
it does not have a considerable effect on cell recruitment.18
SDF1a’s receptor, CXCR4, which several cell types, in-
cluding HSCs and myeloid cells, B-lineage precursors and
plasma cells,20 and granulocytic precursors, express, mediate
its effects.29 Therefore, direct attraction of circulating mono-
cytes and HSCs by SDF1a, which diffuses out of those
FIG. 4. Several cell types
populate heparin–collagen
scaffolds with stromal cell–
derived factor 1 alpha (SDF1a)
are upon implantation.
Heparin–collagen scaffolds
were pre-incubated with
SDF1a before implantation.
After 5 weeks, scaffolds were
collected, and sections were
stained for CD11b (A), CD11c
(B), or CD31 (D). The section
in panel (C) was triple stained
for CD150, CD41, and CD48
to detect hematopoietic stem
cells. Sections were stained for
the various cell markers, as
described in Materials and
Methods, and counterstained
with hematoxylin. Original
magnification:400 (A, B);
630 (C, D). Experiment was
performed twice in duplicate.
Color images available online
at www.liebertonline
.com=ten.
FIG. 5. Cells recruited early
after implantation mainly de-
termine the cell population
present in heparin–collagen
scaffolds after 5 weeks.
Heparin–collagen scaffolds
were implanted in C57Bl6.SJL-
CD45.2 mice. After 1 week,
some scaffolds were collected
for analysis (t¼ 1 wk; A, B),
and others were transplanted
to C57Bl6.SJL-CD45.1 mice.
After another 4 weeks, scaf-
folds were collected (t¼ 5 wk;
C, D). Sections of scaffolds
were stained with anti-CD45.2
monoclonal antibody (mAb)
104 (A, C) or anti-CD45.1 mAb
A20 (B, D), as described in
Materials and Methods, and
counterstained with hematox-
ylin. Original magnification:
100. One out of three experi-
ments is shown. Each experi-
ment was performed in
duplicate. Color images avail-
able online at www
.liebertonline.com=ten.
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scaffolds can easily explain the presence of CD11bþ and
CD11cþ myeloid cells and CD150þCD41–CD48– HSCs in
scaffolds (Fig. 4) 5 weeks after implantation, although it is
expected that most circulating cells are recruited during the
first 24 h after implantation, when SDF1a can still form a
gradient. Therefore, scaffolds should be already considerably
populated by cells within 1 week after implantation, but this
was not observed. On the contrary, only a few cells were
present in scaffolds at that time. Apparently, those cells need
inflammatory cytokines to leave the circulation and to end
up in the scaffold.
After, 3D heparin–collagen scaffolds are implanted into
C57Bl6 mice, several types of hematopoietic and stromal cells
populate the scaffolds. Incubation with SDF1a just before
implantation stimulates the population of these scaffolds by
cells, as long as SDF1a can form a gradient.
Alternatively, therefore, we hypothesize that, instead of
a number of already differentiated cells, SDF1a chemo-
attracts only a few HPCs in the first days after implantation.
These HPCs will subsequently generate their own micro-
environment and, dependent on the micro-environment they
reside in, will proliferate and differentiate along different
lineages, yielding a scaffold containing several cell types
at 5 weeks after implantation. In agreement with this,
4 weeks after transplantation of a scaffold containing only a
few CD45.2þ cells to a CD45.1þ environment, a substantially
higher number of CD45.2þ cells was present in the scaffold
(Fig. 5). These cells can only have been derived from pro-
genitor cells already present at the time of transplantation and
not have been recruited in the weeks thereafter. At the time of
retransplantation, an SDF1a gradient does not exist anymore.
Still, despite of lack of this gradient, CD45.1þ cells were re-
cruited toward the scaffold in the weeks after transplantation.
the local production and secretion of chemokines and other
attracting factors by cells already residing in the scaffold may
explain this. No CD150þCD41–CD48– HSCs could be detected
in sections of scaffolds 1 week after implantation, reflecting
the limited numbers of circulating HSCs of this subset in mice.
CD150þCD41–CD48– HSCs have been reported to represent
only 0.0065% or less of cells in HSC-harboring organs like
normal bone marrow and cyclophosphamide=granulocyte
colony-stimulating factor–mobilized spleen.5
Summary
A release of SDF1a recruited hematopoietic progenitor
cells toward heparinized 3D collagen scaffolds. Such scaf-
folds support the attracted HPCs to form their own micro-
environment and develop along several lineages and attract
other cells. Knowledge about the requisite factors for at-
traction and supporting growth and controlled differentia-
tion of HPCs within scaffolds is of utmost importance for
engineering smart scaffolds without the need for seeding the
scaffolds with cells before implantation.
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